PTC Therapeutics, Inc. provided revenue guidance for the year 2022 and 2023. Total unaudited net revenue for full year 2022 was approximately $710 million. Total unaudited net product revenue for full year 2022 was approximately $535 million.
For the year 2023, the company anticipates total revenues for the full year 2023 to be between $940 million and $1.0 billion. PTC anticipates net product revenues for the DMD franchise for the full year 2023 to be between $545 and $565 million.